 |
|
|
|
Drug-Inducible Promoters hMDR1 and hLRP/MVP
Reference Number TO 03-00097
Promoter
| inducible with:
| induction rate
| published
| hMDR1
| Doxorubicin
| 3 – 10 fold (in vitro) up to 25 fold (in vivo)
| Gene Ther. 1997, 4: pp 544-552, see p 546 Cancer Gene Ther. 2000, 7:6, pp 893-900
|
| Vincristin
| 2,5 – 3fach (in vitro) in vivo
| J Cancer Res. Clin. Oncol. 1996, 122: pp 275-282. Gene Ther. 1997, 4: pp 544-552, see p 548
|
| Taxol
| in vitro
| Gene Ther. 1997, 4: pp 544-552, see p 548
|
| Etoposid
| in vitro
| not yet published
|
| Hyperthermie (4143°C)
| 2 – 7 fold (in vitro) up to 25 fold (in vivo)
| Int. J. Cancer 2002, 98: pp 291-296
|
| not inducible by 5-Fluorouracil
|
| Gene Ther. 1997, 4: pp 544-552, see p 548
| hLRP/MVP
| 5-Fluorouracil
| up to 3.5 fold
| Oncogene, 2005, pp 1-13, see page 6
|
Commercial Opportunity
In-licensing, developing of research tool
Patent situation
I) MDR1 promoter-gene-construct: Priority 1992, granted patent in US, EP (validated in DE, FR, GB).
II) LRP/MVP promoter-gene-construct: Priority 2000, pending in US and EP
|
|
| |
|
|
